<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0021915021000642</prism:url><dc:identifier>doi:10.1016/j.atherosclerosis.2021.02.007</dc:identifier><eid>1-s2.0-S0021915021000642</eid><prism:doi>10.1016/j.atherosclerosis.2021.02.007</prism:doi><pii>S0021-9150(21)00064-2</pii><dc:title>Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe </dc:title><prism:publicationName>Atherosclerosis</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><pubType>dis</pubType><prism:issn>00219150</prism:issn><prism:volume>322</prism:volume><prism:startingPage>77</prism:startingPage><prism:endingPage>81</prism:endingPage><prism:pageRange>77-81</prism:pageRange><dc:format>text/xml</dc:format><prism:coverDate>2021-04-30</prism:coverDate><prism:coverDisplayDate>April 2021</prism:coverDisplayDate><prism:copyright>© 2021 Elsevier B.V. All rights reserved.</prism:copyright><prism:publisher>Elsevier B.V.</prism:publisher><dc:creator>Parini, Paolo</dc:creator><dc:creator>Frikke-Schmidt, Ruth</dc:creator><dc:creator>Tselepis, Alexandros D.</dc:creator><dc:creator>Moulin, Philippe</dc:creator><dc:creator>von Eckardstein, Arnold</dc:creator><dc:creator>Binder, Christoph J.</dc:creator><dc:creator>Catapano, Alberico L.</dc:creator><dc:creator>Ray, Kausik K.</dc:creator><dc:creator>Tokgözoğlu, Lale</dc:creator><dc:description/><openaccess>0</openaccess><openaccessArticle>false</openaccessArticle><openaccessType/><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName/><openaccessSponsorType/><openaccessUserLicense/><link href="https://api.elsevier.com/content/article/pii/S0021915021000642" rel="self"/><link href="https://www.sciencedirect.com/science/article/pii/S0021915021000642" rel="scidir"/></coredata><objects><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="620" size="171750">https://api.elsevier.com/content/object/eid/1-s2.0-S0021915021000642-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="544" height="363" size="113979">https://api.elsevier.com/content/object/eid/1-s2.0-S0021915021000642-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="165" height="164" size="81960">https://api.elsevier.com/content/object/eid/1-s2.0-S0021915021000642-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="146" size="77039">https://api.elsevier.com/content/object/eid/1-s2.0-S0021915021000642-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="2748" size="842829">https://api.elsevier.com/content/object/eid/1-s2.0-S0021915021000642-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2410" height="1606" size="364720">https://api.elsevier.com/content/object/eid/1-s2.0-S0021915021000642-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="524104">https://api.elsevier.com/content/object/eid/1-s2.0-S0021915021000642-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85102128063</scopus-id><scopus-eid>2-s2.0-85102128063</scopus-eid><pubmed-id>33750635</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85102128063" rel="abstract"/><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271064</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291896</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Atherosclerosis</xocs:srctitle>
      <xocs:normalized-srctitle>ATHEROSCLEROSIS</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210216">2021-02-16</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210216">2021-02-16</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210402">2021-04-02</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210402">2021-04-02</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-04-02T04:42:44</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0021915021000642</xocs:eid>
      <xocs:pii-formatted>S0021-9150(21)00064-2</xocs:pii-formatted>
      <xocs:pii-unformatted>S0021915021000642</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.atherosclerosis.2021.02.007</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0021915021X00056</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20221213">2022-12-13T01:11:07.155077Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20210401</xocs:date-search-begin>
      <xocs:date-search-end>20210430</xocs:date-search-end>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1613493216">2021-02-16T16:33:36.732585Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure body affil articletitle auth authfirstini authfull authlast orcid pubtype ref</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0021-9150</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>00219150</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>322</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>322</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 322</xocs:vol-iss-suppl-text>
      <xocs:sort-order>3</xocs:sort-order>
      <xocs:first-fp>77</xocs:first-fp>
      <xocs:last-lp>81</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>77</xocs:first-page>
         <xocs:last-page>81</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>202104</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>April 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-04-01</xocs:cover-date-start>
      <xocs:cover-date-end>2021-04-30</xocs:cover-date-end>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>From the EAS</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>simple-article</xocs:document-type>
      <xocs:document-subtype>dis</xocs:document-subtype>
      <xocs:copyright-line>© 2021 Elsevier B.V. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>TAKINGACTIONEUROPEANATHEROSCLEROSISSOCIETYTARGETSUNITEDNATIONSSUSTAINABLEDEVELOPMENTGOALS2030AGENDAFIGHTATHEROSCLEROTICCARDIOVASCULARDISEASEINEUROPE</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>PARINI</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>P</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Atherosclerotic cardiovascular disease: a global issue</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Challenges in Europe</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Challenges in low- and middle-income countries</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>5</xocs:item-toc-label>
            <xocs:item-toc-section-title>Affordability is crucial</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>6</xocs:item-toc-label>
            <xocs:item-toc-section-title>The role of the EAS</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>7</xocs:item-toc-label>
            <xocs:item-toc-section-title>Smart EAS-led approaches for global health</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>8</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Declaration of competing interest</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1"/>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>MURRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>448</xocs:ref-first-fp>
            <xocs:ref-last-lp>457</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>MURRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1460</xocs:ref-first-fp>
            <xocs:ref-last-lp>1464</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>GLOBALBURDENOFDISEASESTUDY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1736</xocs:ref-first-fp>
            <xocs:ref-last-lp>1788</xocs:ref-last-lp>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>ROTH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>2982</xocs:ref-first-fp>
            <xocs:ref-last-lp>3021</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>YUSUF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2746</xocs:ref-first-fp>
            <xocs:ref-last-lp>2753</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>MORAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>3</xocs:ref-first-fp>
            <xocs:ref-last-lp>16</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>BAE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>AFSHIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1958</xocs:ref-first-fp>
            <xocs:ref-last-lp>1972</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>FULLMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2236</xocs:ref-first-fp>
            <xocs:ref-last-lp>2271</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>GILMORE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1029</xocs:ref-first-fp>
            <xocs:ref-last-lp>1043</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>MACH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>111</xocs:ref-first-fp>
            <xocs:ref-last-lp>188</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>VARTIAINEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>13</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>TIMMIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>12</xocs:ref-first-fp>
            <xocs:ref-last-lp>85</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>WORLDHEALTHORGANIZATIONDATAANDSTATISTICS</xocs:ref-normalized-surname>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>WORLDHEALTHORGANIZATIONDATAANDSTATISTICS</xocs:ref-normalized-surname>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>WORLDHEALTHORGANIZATIONDATAANDSTATISTICS</xocs:ref-normalized-surname>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>HAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1260</xocs:ref-first-fp>
            <xocs:ref-last-lp>1344</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>GLOBALBURDENOFDISEASESTUDY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1923</xocs:ref-first-fp>
            <xocs:ref-last-lp>1994</xocs:ref-last-lp>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>STANAWAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1923</xocs:ref-first-fp>
            <xocs:ref-last-lp>1994</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>GLOBALACTIONPLANFORPREVENTIONCONTROLNONCOMMUNICABLEDISEASES20132020</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>KHATIB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>61</xocs:ref-first-fp>
            <xocs:ref-last-lp>69</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>MURPHY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>e292</xocs:ref-first-fp>
            <xocs:ref-last-lp>e301</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>YUSUF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>216</xocs:ref-first-fp>
            <xocs:ref-last-lp>228</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>ROSHANDEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>672</xocs:ref-first-fp>
            <xocs:ref-last-lp>683</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>MUNOZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1114</xocs:ref-first-fp>
            <xocs:ref-last-lp>1123</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>YUSUF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>216</xocs:ref-first-fp>
            <xocs:ref-last-lp>228</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>FERENCE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1381</xocs:ref-first-fp>
            <xocs:ref-last-lp>1391</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>BRANDTS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>873</xocs:ref-first-fp>
            <xocs:ref-last-lp>876</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>RAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1067</xocs:ref-first-fp>
            <xocs:ref-last-lp>1075</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>BOREN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>2313</xocs:ref-first-fp>
            <xocs:ref-last-lp>2330</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>WILEMON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>217</xocs:ref-first-fp>
            <xocs:ref-last-lp>229</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>VALLEJOVAZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>32</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>PARINIX2021X77</xocs:refkey3>
         <xocs:refkey4lp>PARINIX2021X77X81</xocs:refkey4lp>
         <xocs:refkey4ai>PARINIX2021X77XP</xocs:refkey4ai>
         <xocs:refkey5>PARINIX2021X77X81XP</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-04-02T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-04-02T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2021 Elsevier B.V. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-03-17T14:09:45.573Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type>
         <xocs:funding-source-document source-document-type="pii">S0021915021000642</xocs:funding-source-document>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Boehringer Ingelheim AB</xocs:funding-agency-matched-string>
            <xocs:funding-agency>Boehringer Ingelheim</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100008349</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/2921044/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Sanofi</xocs:funding-agency-matched-string>
            <xocs:funding-agency>Sanofi</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100004339</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/6252001/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>MSD</xocs:funding-agency-matched-string>
            <xocs:funding-agency-acronym>MSD</xocs:funding-agency-acronym>
            <xocs:funding-agency>Meso Scale Diagnostics</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100007054</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/6252001/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Amgen</xocs:funding-agency-matched-string>
            <xocs:funding-agency>Amgen</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100002429</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/6252001/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>European Union</xocs:funding-agency-matched-string>
            <xocs:funding-agency-acronym>EC</xocs:funding-agency-acronym>
            <xocs:funding-agency>European Commission</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100000780</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/6695072/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Lipoprotein Research Stockholm AB</xocs:funding-agency-matched-string>
            <xocs:funding-id>2020-011068</xocs:funding-id>
         </xocs:funding>
         <xocs:funding-text>KR: has equity interests in Pemi31 Therapeutics, NewAmsterdam Pharma and Cargene; company consultant at Regeneron, Sanofi, Amgen, Ionis, Lilly, Cerenis, Abbott, Kowa, Pfizer, Abbvie, Novo Nordisk, BI, Akcea, Novartis, Bayer, MSD, Esperion, Daiichi-Sankyo; has received company speaker honorarium from Dr Reddys, Lupin, Zuelling Pharma, Pfizer, AZ, Amgen, Kowa, Sanofi, Cipla, BI, Novartis, Novo Nordisk, Daiichi-Sankyo; received research grants from Amgen, Regeneron, Daiichi-Sankyo, Sanofi. He is also the president of the European Atherosclerosis Society. </xocs:funding-text>
         <xocs:funding-text>The importance of ASCVD prevention is well recognised in Europe and a driver for policy change. Research on ASCVD (and CMD) has been funded by the European Union since 1984. In 2004, the European Council adopted promotion of heart health, and in 2007 the European Parliament Resolution called for action to tackle ASCVD. Together, these actions have underpinned the development of heart health policies for risk-factor management and prevention in several European countries. Academic societies, such as the EAS and the European Society of Cardiology, have played a key role in developing guidelines for ASCVD prevention, and revising these in accordance with new information, as well as implementing programmes essential for benchmarks of best practice in Europe. </xocs:funding-text>
         <xocs:funding-text>PP: have equity interests in Galmed Pharmaceuticals; has ownership in Lipoprotein Research Stockholm AB; has ownership of patent Japanese Patent No. 2020-011068; company consultant at Ambys Medica; has received company speaker honorarium from Sanofi; received research grants from Boehringer Ingelheim AB and Akcea. </xocs:funding-text>
         <xocs:funding-text>AT: discloses activity as company consultant at Elpen, Libytec and Galenica SA; has received company speaker honorarium from Libytec, Elpen and Amarin; received support in form of fellowship/travel grants from Elpen and Galenica SA; has received research grants from Libytec, Elpen, AstraZeneca and Epsilon Health. </xocs:funding-text>
         <xocs:funding-text>AC: company consultant at Akcea, Amgen, Esperion, Sanofi, MSD, Mylan, Regeneron, Daiichi-Sankyo, Menarini; has received company speaker honorarium from Akcea, Amgen, Sanofi, Esperion, Kowa, Novartis, Medco, MSD, Mylan, Menarini, Recordati, Regeneron, Daiichi-Sankyo, AstraZeneca, Aegerion, Amryt; research grants from Sanofi, Regeneron, Amgen, Mylan, Menarini, Eli Lily; received honorarium from Akcea, Amgen, Sanofi, Esperion, Kowa, Novartis, Mylan, Menarini, MSD, Recordati, Regeneron, Daiichi-Sankyo, AstraZeneca, Aegerion, Amryt. </xocs:funding-text>
      </xocs:funding-list>
      <xocs:article-sharing-framework>
         <xocs:asf-license>https://doi.org/10.15223/policy-017</xocs:asf-license>
         <xocs:asf-license>https://doi.org/10.15223/policy-037</xocs:asf-license>
         <xocs:asf-license>https://doi.org/10.15223/policy-012</xocs:asf-license>
         <xocs:asf-license>https://doi.org/10.15223/policy-029</xocs:asf-license>
         <xocs:asf-license>https://doi.org/10.15223/policy-004</xocs:asf-license>
      </xocs:article-sharing-framework>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0021-9150(21)00064-2</xocs:pii-formatted>
         <xocs:pii-unformatted>S0021915021000642</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0021915021000642</xocs:eid>
         <xocs:doi>10.1016/j.atherosclerosis.2021.02.007</xocs:doi>
         <xocs:cid>271064</xocs:cid>
         <xocs:timestamp>2021-05-17T04:51:55.564328Z</xocs:timestamp>
         <xocs:cover-date-start>2021-04-01</xocs:cover-date-start>
         <xocs:cover-date-end>2021-04-30</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0021915021000642-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0021915021000642/MAIN/application/pdf/03a3526f52c891ca66ddb561564b2d7b/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1645645</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>5</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0021915021000642-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0021915021000642/PREVIEW/image/png/f8467f19ce0982627770b3a8581e4bb2/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>56726</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0021915021000642-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0021915021000642/gr2/DOWNSAMPLED/image/jpeg/82f450be9b0c59aefd99d73a4b4220d5/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>171750</xocs:filesize>
               <xocs:pixel-height>620</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0021915021000642-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0021915021000642/gr1/DOWNSAMPLED/image/jpeg/25f33ca761384364e49d28ebcff54f99/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>113979</xocs:filesize>
               <xocs:pixel-height>363</xocs:pixel-height>
               <xocs:pixel-width>544</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0021915021000642-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0021915021000642/gr2/THUMBNAIL/image/gif/93ddc90bc602edd31e7bad555bf39d50/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>81960</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>165</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0021915021000642-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0021915021000642/gr1/THUMBNAIL/image/gif/4d8aacddf905b25fb3de9de9aa989557/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>77039</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0021915021000642-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0021915021000642/gr2/HIGHRES/image/jpeg/4863f3dc41f5e26a33be37a1c34ef7c7/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>842829</xocs:filesize>
               <xocs:pixel-height>2748</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0021915021000642-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0021915021000642/gr1/HIGHRES/image/jpeg/409283ff68938c0e98d336b238b358fd/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>364720</xocs:filesize>
               <xocs:pixel-height>1606</xocs:pixel-height>
               <xocs:pixel-width>2410</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0021915021000642-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>524104</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10RB6CT58K4/MAIN/application/pdf/3e9ebda3f8aab7269d5467a758dd0e32/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <simple-article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="dis" version="5.6" xml:lang="en">
         <item-info>
            <jid>ATH</jid>
            <aid>16539</aid>
            <ce:pii>S0021-9150(21)00064-2</ce:pii>
            <ce:doi>10.1016/j.atherosclerosis.2021.02.007</ce:doi>
            <ce:copyright type="limited-transfer" year="2021">Elsevier B.V.</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Current prevalence of cardiovascular risk factors in Europe.</ce:simple-para>
                  <ce:simple-para id="fspara0025" view="all">Latest age-standardised estimates for the World Health Organization Europe region, derived from World Health Organization data and statistics. Health 2020 Indicators, and Non-communicable diseases: risk factors and diabetes prevalence [<ce:cross-refs id="crosrefs0025" refid="bib15 bib16 bib17">15–17</ce:cross-refs>].</ce:simple-para>
                  <ce:simple-para id="fspara0015" view="all">Raised blood pressure is defined as systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg; raised fasting glucose is defined as ≥7.0 mm/L.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0010" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0021915021000642/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0020" view="all">Pillars of the European Atherosclerosis Society SMART approaches.</ce:simple-para>
                  <ce:simple-para id="fspara0030" view="all">These activities are crucial to achievement of the UN Sustainable Development Goals for ASCVD as part of the 2030 Agenda.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0015" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0021915021000642/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/>
            </ce:figure>
         </ce:floats>
         <simple-head>
            <ce:dochead id="dhead0010">
               <ce:textfn>EAS Updates</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author author-id="S0021915021000642-fde186c268c0210a908da006726e3269" id="au1" orcid="0000-0002-6541-8542">
                  <ce:given-name>Paolo</ce:given-name>
                  <ce:surname>Parini</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author author-id="S0021915021000642-e7345024a8945c38e99c5d23d91e7c19" id="au2">
                  <ce:given-name>Ruth</ce:given-name>
                  <ce:surname>Frikke-Schmidt</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author author-id="S0021915021000642-d152689c31394777ddfea72b57136bf6" id="au3">
                  <ce:given-name>Alexandros D.</ce:given-name>
                  <ce:surname>Tselepis</ce:surname>
                  <ce:cross-ref id="crosref0025" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author author-id="S0021915021000642-fd108f392c7814a1c442498c82a9a869" id="au4">
                  <ce:given-name>Philippe</ce:given-name>
                  <ce:surname>Moulin</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff4">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author author-id="S0021915021000642-24d5884ca326950630297c9e9f8208f1" id="au5">
                  <ce:given-name>Arnold</ce:given-name>
                  <ce:surname>von Eckardstein</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff5">
                     <ce:sup loc="post">e</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author author-id="S0021915021000642-40ea5e3ed8f3336d5e61182bb9b4eb7f" id="au6">
                  <ce:given-name>Christoph J.</ce:given-name>
                  <ce:surname>Binder</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff6">
                     <ce:sup loc="post">f</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author author-id="S0021915021000642-0e91e7170246b1f6b521e4ee945126ff" id="au7">
                  <ce:given-name>Alberico L.</ce:given-name>
                  <ce:surname>Catapano</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff7">
                     <ce:sup loc="post">g</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author author-id="S0021915021000642-7b563e9162c5b661ea3311805549c5ee" id="au8">
                  <ce:given-name>Kausik K.</ce:given-name>
                  <ce:surname>Ray</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff8">
                     <ce:sup loc="post">h</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author author-id="S0021915021000642-de2513afb75d1eb673b0b16c7e06fa0c" id="au9">
                  <ce:given-name>Lale</ce:given-name>
                  <ce:surname>Tokgözoğlu</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff9">
                     <ce:sup loc="post">i</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0060" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation affiliation-id="S0021915021000642-496618b79970b7e6de0eccac6a8157c9" id="aff1">
                  <ce:label>a</ce:label>
                  <ce:textfn>Department of Medicine and Department of Laboratory Medicine, Karolinska Institutet, and Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Medicine and Department of Laboratory Medicine</sa:organization>
                     <sa:organization>Karolinska Institutet, and Theme Inflammation and Ageing</sa:organization>
                     <sa:organization>Karolinska University Hospital</sa:organization>
                     <sa:city>Stockholm</sa:city>
                     <sa:country>Sweden</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Department of Medicine and Department of Laboratory Medicine, Karolinska Institutet, and Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden</ce:source-text>
               </ce:affiliation>
               <ce:affiliation affiliation-id="S0021915021000642-932e858412c98e87931f5575a6858400" id="aff2">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen and Department of Clinical Biochemistry, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Clinical Medicine</sa:organization>
                     <sa:organization>Faculty of Health and Medical Science</sa:organization>
                     <sa:organization>University of Copenhagen and Department of Clinical Biochemistry</sa:organization>
                     <sa:organization>Rigshospitalet Copenhagen University Hospital</sa:organization>
                     <sa:city>Copenhagen</sa:city>
                     <sa:country>Denmark</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen and Department of Clinical Biochemistry, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark</ce:source-text>
               </ce:affiliation>
               <ce:affiliation affiliation-id="S0021915021000642-1b4036c859fb1965fc368000d491910c" id="aff3">
                  <ce:label>c</ce:label>
                  <ce:textfn>Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110, Ioannina, Greece</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Atherothrombosis Research Centre/Laboratory of Biochemistry</sa:organization>
                     <sa:organization>Department of Chemistry</sa:organization>
                     <sa:organization>University of Ioannina</sa:organization>
                     <sa:city>Ioannina</sa:city>
                     <sa:postal-code>45110</sa:postal-code>
                     <sa:country>Greece</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110, Ioannina, Greece</ce:source-text>
               </ce:affiliation>
               <ce:affiliation affiliation-id="S0021915021000642-14470343a303171b914e7dd301c9960c" id="aff4">
                  <ce:label>d</ce:label>
                  <ce:textfn>Department of Endocrinology, GHE, Hospices Civils de Lyon, Univ-Lyon, CarMeN Laboratory, Inserm UMR 1060, CENS-ELI, Univ-Lyon1, 69003 Lyon, France</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Endocrinology</sa:organization>
                     <sa:organization>GHE</sa:organization>
                     <sa:organization>Hospices Civils de Lyon</sa:organization>
                     <sa:organization>Univ-Lyon</sa:organization>
                     <sa:organization>CarMeN Laboratory</sa:organization>
                     <sa:organization>Inserm UMR 1060</sa:organization>
                     <sa:organization>CENS-ELI</sa:organization>
                     <sa:organization>Univ-Lyon1</sa:organization>
                     <sa:city>Lyon</sa:city>
                     <sa:postal-code>69003</sa:postal-code>
                     <sa:country>France</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0025">Department of Endocrinology, GHE, Hospices Civils de Lyon, Univ-Lyon, CarMeN Laboratory, Inserm UMR 1060, CENS-ELI, Univ-Lyon1, 69003 Lyon, France</ce:source-text>
               </ce:affiliation>
               <ce:affiliation affiliation-id="S0021915021000642-43c2bde273e63b0d68b2953484351554" id="aff5">
                  <ce:label>e</ce:label>
                  <ce:textfn>Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Institute of Clinical Chemistry</sa:organization>
                     <sa:organization>University Hospital Zurich</sa:organization>
                     <sa:city>Zurich</sa:city>
                     <sa:country>Switzerland</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0030">Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland</ce:source-text>
               </ce:affiliation>
               <ce:affiliation affiliation-id="S0021915021000642-8ea3f48179511f68dec63fb0318ded9c" id="aff6">
                  <ce:label>f</ce:label>
                  <ce:textfn>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Laboratory Medicine</sa:organization>
                     <sa:organization>Medical University of Vienna</sa:organization>
                     <sa:state>Vienna</sa:state>
                     <sa:country>Austria</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0035">Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria</ce:source-text>
               </ce:affiliation>
               <ce:affiliation affiliation-id="S0021915021000642-97700c8754fcd784e2c0e69d89c5b9b5" id="aff7">
                  <ce:label>g</ce:label>
                  <ce:textfn>Department of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, and IRCCS MultiMedica, Milan, Italy</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Pharmacological and Biomolecular Sciences</sa:organization>
                     <sa:organization>Università Degli Studi di Milano, and IRCCS MultiMedica</sa:organization>
                     <sa:city>Milan</sa:city>
                     <sa:country>Italy</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0040">Department of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, and IRCCS MultiMedica, Milan, Italy</ce:source-text>
               </ce:affiliation>
               <ce:affiliation affiliation-id="S0021915021000642-2e7637af0388f86e070a1ffe9f647e94" id="aff8">
                  <ce:label>h</ce:label>
                  <ce:textfn>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Imperial Centre for Cardiovascular Disease Prevention</sa:organization>
                     <sa:organization>Department of Primary Care and Public Health</sa:organization>
                     <sa:organization>Imperial College London</sa:organization>
                     <sa:city>London</sa:city>
                     <sa:country>UK</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0045">Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London</ce:source-text>
               </ce:affiliation>
               <ce:affiliation affiliation-id="S0021915021000642-9515a4c7e93530f1ceaac86cb62facaf" id="aff9">
                  <ce:label>i</ce:label>
                  <ce:textfn>Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Cardiology</sa:organization>
                     <sa:organization>Hacettepe University Faculty of Medicine</sa:organization>
                     <sa:city>Ankara</sa:city>
                     <sa:country>Turkey</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0050">Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author. Division of Endocrinology, Department of Medicine, Karolinska Institutet, C2:94, Karolinska University Hospital, 14186 Stockholm, Sweden.</ce:text>
                  <sa:affiliation>
                     <sa:organization>Division of Endocrinology</sa:organization>
                     <sa:organization>Department of Medicine</sa:organization>
                     <sa:organization>Karolinska Institutet</sa:organization>
                     <sa:organization>C2:94</sa:organization>
                     <sa:organization>Karolinska University Hospital</sa:organization>
                     <sa:address-line>14186 Stockholm</sa:address-line>
                     <sa:country>Sweden</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author. Department of Cardiology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey.</ce:text>
                  <sa:affiliation>
                     <sa:organization>Department of Cardiology</sa:organization>
                     <sa:organization>Hacettepe University Faculty of Medicine</sa:organization>
                     <sa:city>Ankara</sa:city>
                     <sa:postal-code>06100</sa:postal-code>
                     <sa:country>Turkey</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="4" month="2" year="2021"/>
            <ce:date-accepted day="5" month="2" year="2021"/>
         </simple-head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0010">Introduction</ce:section-title>
                  <ce:para id="p0010" view="all">In 2015, the United Nations launched the Sustainable Development Goals 2030 Agenda as a universal call to action to end poverty, protect the planet, and improve the lives and prospects for all [<ce:cross-ref id="crosref0065" refid="bib1">1</ce:cross-ref>]. The 17 goals of this Agenda, adopted by all United Nations (UN) member states, are to be delivered within 15 years. As only 10 years remain, accelerated action is needed, with world leaders calling for a Decade of Action in 2019 to achieve these goals. According to the UN Secretary-General, urgent action is needed on three levels: 1) globally, to secure greater leadership, more resources and smarter solutions; 2) locally, to ensure smooth transition in policies, budgets, institutions and regulatory frameworks of governments, cities and local authorities; and 3) societally, to ensure an unstoppable movement of change by targeting all stakeholders. In accordance with its mission, the European Atherosclerosis Society (EAS) has committed itself to the Sustainable Development Goals 2030 Agenda and will act on all three levels.</ce:para>
                  <ce:para id="p0015" view="all">Of paramount importance for the EAS is the third goal of the Sustainable Development 2030 Agenda, Good Health and Well-Being. Ensuring healthy lives and promoting well-being—for all genders, ethnicities, social classes, and ages—with universal access to healthcare is crucial, since low socioeconomic status is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). Yet in 2017, less than half of the global population received essential healthcare services, and this is not likely to change much by 2030. Furthermore, the EAS should contemplate how to help develop screening and implementation for primary care in low income countries. Combatting newly described environmental risk factors, such as air pollution and noise, is also becoming important.</ce:para>
                  <ce:para id="p0020" view="all">A key target of the Good Health and Well-Being goal is reducing by one-third premature mortality from non-communicable disease (NCD), the major cause of death globally [<ce:cross-refs id="crosrefs0010" refid="bib2 bib3 bib4 bib5">2–5</ce:cross-refs>]. Preventing, treating and promoting mental health and well-being, particularly in lower- and middle-income (LMI) countries are essential. Early detection and management of determinants of health, and support for research, development, and access to medicines for NCDs that primarily affect these countries are needed. Legacy and succession planning ensure sustainability; expanding scholarships to developing countries, particularly under-resourced areas such as sub-Saharan Africa, is one approach to this.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0015">Atherosclerotic cardiovascular disease: a global issue</ce:section-title>
                  <ce:para id="p0025" view="all">Cardiovascular disease is one of the major NCDs, with ASCVD, which includes ischaemic heart disease and ischaemic stroke, among the most prevalent. As the underlying risk factors become more common, ASCVD poses a threat to health in most regions of the world [<ce:cross-ref id="crosref0070" refid="bib6">6</ce:cross-ref>,<ce:cross-ref id="crosref0075" refid="bib7">7</ce:cross-ref>]. Superimposed on this is a global health crisis unlike any other caused by a communicable disease (COVID-19), which causes human suffering, destabilises the global economy, and overturns the lives of almost every person. Patients with pre-existing ASCVD and cardiometabolic diseases (CMD) have an increased propensity for worse outcomes from COVID-19 [<ce:cross-ref id="crosref0080" refid="bib8">8</ce:cross-ref>].</ce:para>
                  <ce:para id="p0030" view="all">The Global Burden of Disease (GBD) Study is an unparalleled resource for trends in the major causes of death, disability and associated risk factors [<ce:cross-ref id="crosref0085" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0090" refid="bib6">6</ce:cross-ref>,<ce:cross-ref id="crosref0095" refid="bib9">9</ce:cross-ref>], as well as access to quality healthcare [<ce:cross-ref id="crosref0100" refid="bib10">10</ce:cross-ref>]. These data provide the foundation for global, regional, and national health policies for tackling ASCVD, the leading cause of disease burden in the world. In 2019, ASCVD was responsible for about one-third of all deaths, 8.9 million among women and 9.6 million among men [<ce:cross-ref id="crosref0105" refid="bib5">5</ce:cross-ref>], with more than one in 20 deaths in those younger than 50 years [<ce:cross-ref id="crosref0110" refid="bib5">5</ce:cross-ref>].</ce:para>
                  <ce:para id="p0035" view="all">The situation is complicated by evidence suggesting that improvement in ASCVD mortality in high-income countries achieved over the last 40 years is declining, as ASCVD events increase [<ce:cross-ref id="crosref0115" refid="bib5">5</ce:cross-ref>]. Superimposed on this is an epidemic of ASCVD and CMD in LMI countries, driven by rapid urbanisation, adoption of westernised energy-dense diets (high-fat, high-sugar and excess calories), and sedentary lifestyles. CMD comprises various adverse health profiles including metabolic syndrome, type 2 diabetes mellitus and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. In addition, air pollution, together with a shift in tobacco marketing toward LMI countries due to restrictive regulation in high-income countries, also negatively impact the ASCVD epidemic [<ce:cross-ref id="crosref0120" refid="bib11">11</ce:cross-ref>].</ce:para>
                  <ce:para id="p0040" view="all">Until recently, the lack of reliable definition of dietary patterns across regions hampered efforts to evaluate the impact of diet on global health [<ce:cross-ref id="crosref0125" refid="bib9">9</ce:cross-ref>]. The GBD initiative addressed this by systematically collecting data from 195 countries to characterise intake of 15 foods and nutrients that are either underconsumed (i.e., fruits, vegetables, legumes, whole grains, nuts and seeds, milk, fibre, calcium, omega-3 fatty acids from seafood, and polyunsaturated fatty acids) or overconsumed (i.e., red meat, processed meat, sugar-sweetened beverages, <ce:italic>trans</ce:italic>-fatty acids, and sodium). It is clear that trends in ASCVD, and more generally cardiovascular disease, reflect dietary risks. In 2019, nearly 8 million deaths were potentially attributable to dietary risks, reflecting increases in absolute and relative (by almost 50%) ASCVD burden over the last 30 years [<ce:cross-ref id="crosref0130" refid="bib5">5</ce:cross-ref>]. The GBD initiative also analysed how low socioeconomic and education status impacted the ability to access healthy diets, as well as the roles of physical activity, smoking, and air pollutants. Clearly, much of the global disease burden is preventable by optimising/correcting diet, lifestyle, and environmental factors, as the fundamental foundation for effective prevention strategies [<ce:cross-ref id="crosref0135" refid="bib12">12</ce:cross-ref>].</ce:para>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0020">Challenges in Europe</ce:section-title>
                  <ce:para id="p0045" view="all">Industrialisation, urbanisation and economic development in Europe have led to substantial social transition in Europe. Like other high-income regions, affluence has had benefits, improving health outcomes and life expectancy. Better management of risk factors led to a decline in the age-standardised incidence of ASCVD events and cardiovascular death, especially in Northern and Western European countries [<ce:cross-ref id="crosref0140" refid="bib2">2</ce:cross-ref>]. For example, in Finland, a comprehensive national prevention programme led to population decreases in serum cholesterol, blood pressure, and smoking, as well as 84% reduction in coronary mortality, between 1972 and 2014 [<ce:cross-ref id="crosref0145" refid="bib13">13</ce:cross-ref>].</ce:para>
                  <ce:para id="p0050" view="all">Individual countries in Europe are at different stages of transition in the prevalence of risk factors, prevention strategies and policy. Despite this, efforts over the past 20 years have favourably impacted major risk factors for ASCVD [<ce:cross-ref id="crosref0150" refid="bib14">14</ce:cross-ref>]; currently ~24% are smokers, 23% have raised blood pressure and 16% have elevated total cholesterol ≥6.2 mmol/L (<ce:cross-ref id="crosref0155" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/>) [<ce:cross-refs id="crosrefs0015" refid="bib15 bib16 bib17">15–17</ce:cross-refs>]. Such gains have been achieved using a variety of strategies. These include, for smoking, targeted taxation and pricing of tobacco products, the introduction of plain packaging, and bans on tobacco advertising; and for blood pressure, reformulation of food products with less salt, and implementation of guidelines. Elimination of industrial <ce:italic>trans</ce:italic>-fats, improved package labelling, and public education programmes, with better treatments and attention to patient compliance, have contributed to a decrease in median cholesterol levels in Europe, from 5.5 to 5.1 mmol/L [<ce:cross-ref id="crosref0160" refid="bib16">16</ce:cross-ref>]. However, affluence has also negatively impacted other areas. Europe is facing a crisis in obesity and diabetes, with the median age-standardised prevalence increasing 2-3-fold over the last 30 years [<ce:cross-ref id="crosref0165" refid="bib16">16</ce:cross-ref>]. Diabetes affects 3.9% of the global population, but 7.3% of those in Europe [<ce:cross-ref id="crosref0170" refid="bib17">17</ce:cross-ref>]. Overall, one in three adults living in Europe, higher among women, have insufficient physical activity levels [<ce:cross-ref id="crosref0175" refid="bib16">16</ce:cross-ref>]. Fat and energy consumption are also increasing in Eastern Europe.</ce:para>
                  <ce:para id="p0055" view="all">With inpatient care accounting for over 50% of the total ASCVD healthcare expenditure in Europe, preventive strategies offer a cost-effective approach to reducing disease and improving quality of life. Studies such as EUROASPIRE and EURIKA, which track the clinical implementation of scientific knowledge on lifestyle, treatment and risk factor control, are crucial to fill the gaps between the science and what is done in clinical practice. Fighting obesity and diabetes at both the individual and population level has involved targeting the food industry to implement better diets, and promoting physical activity from very early in life.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0025">Challenges in low- and middle-income countries</ce:section-title>
                  <ce:para id="p0060" view="all">NCD is a growing problem in LMI regions [<ce:cross-ref id="crosref0180" refid="bib18">18</ce:cross-ref>], accounting for ~80% of global deaths from ASCVD [<ce:cross-ref id="crosref0185" refid="bib4">4</ce:cross-ref>]. Metabolic risk factors, such as high cholesterol, raised systolic blood pressure, and increased body mass index (BMI), are now as common in these regions as in high-income countries. Between 1990 and 2017, the summary exposure value (SEV), a risk-weighted prevalence measure, showed a doubling of BMI in 47 countries, of which 37 had a socio-demographic Index (SDI) less than the median [<ce:cross-ref id="crosref0190" refid="bib19">19</ce:cross-ref>].</ce:para>
                  <ce:para id="p0065" view="all">Importantly, trends in metabolic risk are outpacing expectations based on development [<ce:cross-ref id="crosref0195" refid="bib19">19</ce:cross-ref>]. Therapeutic management of high cholesterol and raised blood pressure, although easy to implement and cost-effective, is inaccessible for many [<ce:cross-ref id="crosref0200" refid="bib10">10</ce:cross-ref>,<ce:cross-ref id="crosref0205" refid="bib20">20</ce:cross-ref>]. Public health preventive efforts should be guided by income-related trends (measured by SDI). For example, given that SEVs for smoking are higher for men than women at all SDI levels, anti-smoking interventions in LMI regions should primarily target men to be most effective, whereas in higher-income regions both men and women should be targeted similarly [<ce:cross-ref id="crosref0210" refid="bib19">19</ce:cross-ref>].</ce:para>
               </ce:section>
               <ce:section id="sec5" view="all">
                  <ce:label>5</ce:label>
                  <ce:section-title id="sectitle0030">Affordability is crucial</ce:section-title>
                  <ce:para id="p0070" view="all">Critical to efforts to improve global health are cost-effective prevention strategies and efficient delivery of therapies across different income regions. Aggressive education and prevention, with early treatment, are essential to ensure ‘no-one is left behind’ in meeting the Sustainable Development Goals 2030 Agenda.</ce:para>
                  <ce:para id="p0075" view="all">Affordability is a particular issue for LMI regions. Premature NCD mortality in LMI countries is more than double that of high-income countries [<ce:cross-ref id="crosref0215" refid="bib5">5</ce:cross-ref>], due in part to poor access to healthcare services. As recognised by the UN, this needs urgent action <ce:italic>(UN General Assembly. High-level meeting on prevention and control of non-communicable diseases; New York, USA; Sept 19–20, 2011)</ce:italic>. Even if there is access to healthcare, long-term unaffordability of effective preventive therapies is a major deterrent. According to the nine global World Health Organization (WHO) targets for 2025, 50% of eligible individuals should receive drug therapy and counselling to prevent ASCVD [<ce:cross-ref id="crosref0220" refid="bib21">21</ce:cross-ref>]. Yet the reality is in stark contrast. The Prospective Urban Rural Epidemiology (PURE) study showed that secondary prevention medicines (aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and statins) were either unavailable or unaffordable in over 80% of communities and households in 18 middle-income, lower middle-income, and low-income countries [<ce:cross-ref id="crosref0225" refid="bib22">22</ce:cross-ref>]. Among individuals reporting ASCVD, inequalities in socioeconomic status clearly impacted the use of these therapies [<ce:cross-ref id="crosref0230" refid="bib23">23</ce:cross-ref>]; only 2% of those in Tanzania versus 91% in Sweden received at least one medicine, and none in South Africa, Tanzania, and Zimbabwe versus 49% in Canada received all three. The strongest predictors of inequality were public health expenditure and overall use of secondary prevention medicines [<ce:cross-ref id="crosref0235" refid="bib23">23</ce:cross-ref>].</ce:para>
                  <ce:para id="p0080" view="all">Universal health coverage will slowly heal some of these disparities. Healthcare systems should focus on screening, improving health literacy and, where needed, using inexpensive combinations of generic therapies which lower cholesterol and blood pressure [<ce:cross-refs id="crosrefs0020" refid="bib24 bib25 bib26">24–26</ce:cross-refs>]. Polypills offer the advantages of lower cost and reduced pill burden, thus improving adherence. In intermediate-risk subjects, intervention with a polypill decreased the risk of cardiovascular events by 20% [<ce:cross-ref id="crosref0240" refid="bib27">27</ce:cross-ref>]. Using information on genetic variants for early targeting of cholesterol and blood pressure could substantially decrease the number of coronary heart disease events and thus reduce the global burden of ASCVD [<ce:cross-ref id="crosref0245" refid="bib28">28</ce:cross-ref>]. The challenge is reliance on self-management of essentially a silent condition, as risk factor control offers no immediate health benefits or feeling of well-being. Greater use of polypill-like strategies should be accompanied by methods to improve adherence, possibly with digital health tools readily available on smart phones. In addition, emerging therapies with a long duration of efficacy after single administration offer promise. While cost needs to be addressed, the use of such therapies would enable healthcare assistants, pharmacists and nurses in remote areas to lower cholesterol through a single injection each year. If repeated annually, population-level coverage to lower exposure may be achieved [<ce:cross-ref id="crosref0250" refid="bib29">29</ce:cross-ref>,<ce:cross-ref id="crosref0255" refid="bib30">30</ce:cross-ref>]. These therapies could work well (cost permitting), tapping into infrastructure that already delivers vaccination programmes or deals with communicable disease outbreaks.</ce:para>
               </ce:section>
               <ce:section id="sec6" view="all">
                  <ce:label>6</ce:label>
                  <ce:section-title id="sectitle0035">The role of the EAS</ce:section-title>
                  <ce:para id="p0085" view="all">The importance of ASCVD prevention is well recognised in Europe and a driver for policy change. Research on ASCVD (and CMD) has been funded by the European Union since 1984. In 2004, the European Council adopted promotion of heart health, and in 2007 the European Parliament Resolution called for action to tackle ASCVD. Together, these actions have underpinned the development of heart health policies for risk-factor management and prevention in several European countries. Academic societies, such as the EAS and the European Society of Cardiology, have played a key role in developing guidelines for ASCVD prevention, and revising these in accordance with new information, as well as implementing programmes essential for benchmarks of best practice in Europe.</ce:para>
                  <ce:para id="p0090" view="all">Aligning with its mission to advance and exchange knowledge on the causes, risk factors, prevention and treatment of ASCVD, the EAS has made, and continues to make, important contributions in research, education, and advocacy to reduce the burden of ASCVD in Europe. Insights from EAS consensus papers about lipid and lipoprotein-related risk factors and their management have been translated to guidelines [<ce:cross-ref id="crosref0260" refid="bib12">12</ce:cross-ref>,<ce:cross-ref id="crosref0265" refid="bib31">31</ce:cross-ref>]. Collaboration between the EAS-led Familial Hypercholesterolemia Studies Collaboration (FHSC), the largest global database on familial hypercholesterolemia (FH), patient organisations and the World Heart Federation, led a global call to action on FH [<ce:cross-ref id="crosref0270" refid="bib32">32</ce:cross-ref>]. Education, either face-to-face, online, or via the yearly EAS congress, allows scientists and healthcare professionals to keep up to date on the latest developments and best practice. Finally, the EAS offers support via grants and educational programmes tailored to the needs of young scientists and healthcare professionals.</ce:para>
               </ce:section>
               <ce:section id="sec7" view="all">
                  <ce:label>7</ce:label>
                  <ce:section-title id="sectitle0040">Smart EAS-led approaches for global health</ce:section-title>
                  <ce:para id="p0095" view="all">This proactive role of the EAS is crucial to achieving the UN Sustainable Development Goals 2030 Agenda. Underpinned by fundamental pillars (<ce:cross-ref id="crosref0275" refid="fig2">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/>), EAS-led sustainable strategies will ensure cost-effectiveness and affordability, taking into account cultural and socio-economic diversity across Europe. A key pillar of these activities is clinical guidance for the most effective primary prevention strategies targeting all modifiable ASCVD risk factors, including environmental risk factors.</ce:para>
                  <ce:para id="p0100" view="all">Research initiatives, such as the FHSC and the more recently launched homozygous FH International Clinical Collaboration (HICC) registry, are fundamental to change [<ce:cross-ref id="crosref0280" refid="bib33">33</ce:cross-ref>]. By driving the development of a network of lipid clinics and referral centres for genetic testing in various countries, ensuring wider access to specialist services for FH diagnosis and management, the FHSC will raise standards of care for FH in Europe and beyond. Building on the success of the FHSC, future EAS plans include registries for rare genetic disorders of lipid metabolism, involving patients from various countries, including LMI regions. Collaboration between the EAS and other academic societies is critical to evaluating polygenic ASCVD risk scores to select the most appropriate for improving the precision of prevention and treatment policies.</ce:para>
                  <ce:para id="p0105" view="all">Education using smart strategies represents another EAS pillar for achievement of global health. Education initiatives directed not only to healthcare professionals and researchers, but also to decision makers and the general population, aim to increase awareness of the role of lifestyle risk factors (e.g., smoking, poor quality diets, and physical inactivity), environmental risk factors (e.g., air pollution by particulate matters and fuel exhausts), and low socioeconomic status.</ce:para>
                  <ce:para id="p0110" view="all">Optimising the value of more expensive therapies by specifically targeting those that derive greatest benefit, is particularly important for LMI countries. Key to success is collaboration with national atherosclerosis societies worldwide, so that healthcare professionals of these countries can take advantage of the myriad of EAS educational activities. Supporting career development of high-quality young scientists, especially those from LMI countries where funding is difficult to secure, is another pillar of EAS smart approaches to achieve the Sustainable Development Goals 2030 Agenda.</ce:para>
               </ce:section>
               <ce:section id="sec8" role="conclusion" view="all">
                  <ce:label>8</ce:label>
                  <ce:section-title id="sectitle0045">Conclusion</ce:section-title>
                  <ce:para id="p0115" view="all">Globally, achievement of the UN Sustainable Development Goals 2030 Agenda will only be possible by collaboration on multiple levels among different stakeholders. Academic societies such as the EAS have a vital part to play, in contributing and implementing scientific evidence. While the current pandemic has hampered some of these efforts, the pillars of education, research, communication and collaboration are crucial to better implementation of clinical guidance and achievement of these global goals.</ce:para>
               </ce:section>
               <ce:section id="sec9" view="all">
                  <ce:section-title id="sectitle0050">Declaration of competing interest</ce:section-title>
                  <ce:para id="p0120" view="all">PP: have equity interests in Galmed Pharmaceuticals; has ownership in Lipoprotein Research Stockholm AB; has ownership of patent Japanese Patent No. 2020-011068; company consultant at Ambys Medica; has received company speaker honorarium from Sanofi; received research grants from Boehringer Ingelheim AB and Akcea.</ce:para>
                  <ce:para id="p0125" view="all">RFS: discloses company consultancy at Novo Nordisk Scientific advisory board; has received company speaker honorarium from Amgen.</ce:para>
                  <ce:para id="p0130" view="all">AT: discloses activity as company consultant at Elpen, Libytec and Galenica SA; has received company speaker honorarium from Libytec, Elpen and Amarin; received support in form of fellowship/travel grants from Elpen and Galenica SA; has received research grants from Libytec, Elpen, AstraZeneca and Epsilon Health.</ce:para>
                  <ce:para id="p0135" view="all">PM: company consultant at Akcea int, Akcea France, Boehringer and Sanofi; has received company speaker honorarium from Akcea int, Novo Nordisk, MSD, Akcea France and Sanofi; participation in clinical trials with Amgen, Novo Nordisk and Sanofi; has received support in form of fellowship/travel grants from Boehringer, Janssen and MSD; has received research grants from Akcea France.</ce:para>
                  <ce:para id="p0140" view="all">AvE: company consultant at Amgen Switzerland, Sanofi-Aventis Switzerland, Daiichi Switzerland; has received company speaker honorarium from Amgen Germany and Sanofi-Aventis.</ce:para>
                  <ce:para id="p0145" view="all">CB: company consultant at Akcea, Daiichi-Sankyo and Amgen; has received company speaker honorarium from Amgen and Novartis.</ce:para>
                  <ce:para id="p0150" view="all">AC: company consultant at Akcea, Amgen, Esperion, Sanofi, MSD, Mylan, Regeneron, Daiichi-Sankyo, Menarini; has received company speaker honorarium from Akcea, Amgen, Sanofi, Esperion, Kowa, Novartis, Medco, MSD, Mylan, Menarini, Recordati, Regeneron, Daiichi-Sankyo, AstraZeneca, Aegerion, Amryt; research grants from Sanofi, Regeneron, Amgen, Mylan, Menarini, Eli Lily; received honorarium from Akcea, Amgen, Sanofi, Esperion, Kowa, Novartis, Mylan, Menarini, MSD, Recordati, Regeneron, Daiichi-Sankyo, AstraZeneca, Aegerion, Amryt.</ce:para>
                  <ce:para id="p0155" view="all">KR: has equity interests in Pemi31 Therapeutics, NewAmsterdam Pharma and Cargene; company consultant at Regeneron, Sanofi, Amgen, Ionis, Lilly, Cerenis, Abbott, Kowa, Pfizer, Abbvie, Novo Nordisk, BI, Akcea, Novartis, Bayer, MSD, Esperion, Daiichi-Sankyo; has received company speaker honorarium from Dr Reddys, Lupin, Zuelling Pharma, Pfizer, AZ, Amgen, Kowa, Sanofi, Cipla, BI, Novartis, Novo Nordisk, Daiichi-Sankyo; received research grants from Amgen, Regeneron, Daiichi-Sankyo, Sanofi. He is also the president of the European Atherosclerosis Society.</ce:para>
                  <ce:para id="p0160" view="all">LT: company consultant at Abbott, Amgen, Bayer, MSD, Mylan, Sanofi; has received company speaker honorarium from Abbott, Actelion, Amgen, Bayer, Daiichi-Sankyo, MSD, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati; trial participation Amgen.</ce:para>
               </ce:section>
            </ce:sections>
         </body>
         <simple-tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0055">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:title>
                              <sb:maintitle>The sustainable development Agenda</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>Available at</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0010" xlink:href="https://www.un.org/sustainabledevelopment/development-agenda/" xlink:type="simple">https://www.un.org/sustainabledevelopment/development-agenda/</ce:inter-ref>
                              <sb:date-accessed day="15" month="1" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">The Sustainable Development Agenda. Available at https://www.un.org/sustainabledevelopment/development-agenda/(Accessed 15 January 2021))</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.J.L.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Lopez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Measuring the global burden of disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>369</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>448</sb:first-page>
                              <sb:last-page>457</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">Murray CJL, Lopez AD. Measuring the Global Burden of Disease. N Engl J Med 2013;369: 448-457.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.J.L.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Lopez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Measuring global health: motivation and evolution of the global burden of disease study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>390</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1460</sb:first-page>
                              <sb:last-page>1464</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">Murray CJL, Lopez AD, Measuring global health: motivation and evolution of the Global Burden of Disease Study. Lancet 2017;390:1460-1464.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>Global Burden of Disease Study</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>392</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1736</sb:first-page>
                              <sb:last-page>1788</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">Global Burden of Disease Study. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736-1788.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Roth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Mensah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.O.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Addolorato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ammirati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Baddour</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Coll. Cardiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>76</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2982</sb:first-page>
                              <sb:last-page>3021</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 Study. J Am Coll Cardiol 2020;76:2982-3021.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yusuf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ôunpuu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Anand</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global burden of cardiovascular diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Circulation</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2746</sb:first-page>
                              <sb:last-page>2753</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Circulation 2001;104:2746-2753.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Moran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Roth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Narula</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Mensah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global cardiovascular disease atlas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Glob Heart</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3</sb:first-page>
                              <sb:last-page>16</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">Moran AE, Roth GA, Narula J, Mensah GA, 1990-2010 global cardiovascular disease atlas. Glob Heart 2014;9:3-16.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bae</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.N.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Shim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Heart</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <ce:doi>10.1136/heartjnl-2020-317901</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart 2020; doi: 10.1136/heartjnl-2020-317901.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Afshin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Fay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cornaby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ferrara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Salama</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Health effects of dietary risks in 195 countries, 1990,2013;2017: a systematic analysis for the Global Burden of Disease Study 2017</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>393</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1958</sb:first-page>
                              <sb:last-page>1972</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">Afshin AP, Sur J, Fay KR, Cornaby L, Ferrara G, Salama GS, et al. Health effects of dietary risks in 195 countries, 1990,2013;2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2019;393:1958-1972.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Fullman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yearwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Abay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Abbafati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Abd-Allah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Abdela</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the global burden of disease study 2016</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>391</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2236</sb:first-page>
                              <sb:last-page>2271</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">Fullman N, Yearwood J, Abay SM, Abbafati C, Abd-Allah F, Abdela J, et al. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet 2018;391:2236-2271.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Gilmore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Fooks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Drope</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Bialous</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exposing and addressing tobacco industry conduct in low-income and middle-income countries</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>385</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1029</sb:first-page>
                              <sb:last-page>1043</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">Gilmore AB, Fooks G, Drope J, Bialous SA, Jackson RR. Exposing and addressing tobacco industry conduct in low-income and middle-income countries. Lancet 2015;385:1029-1043.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Mach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Baigent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Catapano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Koskinas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Casula</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Badimon</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. Heart J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111</sb:first-page>
                              <sb:last-page>188</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-188.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Vartiainen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The north karelia project: cardiovascular disease prevention in Finland</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Glob Cardiol Sci Pract</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2018</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">Vartiainen E. The North Karelia Project: Cardiovascular disease prevention in Finland. Glob Cardiol Sci Pract 2018;2018(2):13.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.N.</ce:given-name>
                                 <ce:surname>Timmis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.P.</ce:given-name>
                                 <ce:surname>Townsend</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Torbica</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Lettino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Petersen</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cardiovascular disease statistics 2019</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. Heart J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12</sb:first-page>
                              <sb:last-page>85</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">Timmis AN, Townsend CP, Gale A, Torbica M, Lettino SE, Petersen EA, et al. Cardiovascular disease statistics 2019. Eur Heart J 2019;41:12-85.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>World Health Organization data and statistics</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Health 2020 indicators: Tobacco smoking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0015" xlink:href="https://gateway.euro.who.int/en/indicators/hfa_421-3010-of-regular-daily-smokers-in-the-population-age-15plus/" xlink:type="simple">https://gateway.euro.who.int/en/indicators/hfa_421-3010-of-regular-daily-smokers-in-the-population-age-15plus/</ce:inter-ref>
                              <sb:date-accessed day="15" month="1" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">World Health Organization data and statistics. Health 2020 indicators: Tobacco smoking; https://gateway.euro.who.int/en/indicators/hfa_421-3010-of-regular-daily-smokers-in-the-population-age-15plus/(Accessed 15 January 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>World Health Organization data and statistics</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Non-communicable diseases: risk factors. Blood pressure</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:comment>Cholesterol: <ce:inter-ref id="intref0020" xlink:href="https://apps.who.int/gho/data/node.main.A887?lang=en;%20Overweight/Obesity" xlink:type="simple">https://apps.who.int/gho/data/node.main.A887?lang=en; Overweight/Obesity</ce:inter-ref>
                        </sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0025" xlink:href="https://apps.who.int/gho/data/node.main.A875STANDARD" xlink:type="simple">https://apps.who.int/gho/data/node.main.A875STANDARD</ce:inter-ref>
                              <sb:date-accessed day="15" month="1" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0030" xlink:href="https://apps.who.int/gho/data/node.main.BMIOBESITYA?lang=en" xlink:type="simple">https://apps.who.int/gho/data/node.main.BMIOBESITYA?lang=en</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">World Health Organization data and statistics. Non-communicable diseases: Risk factors. Blood Pressure. https://apps.who.int/gho/data/node.main.A875STANDARD; Cholesterol: https://apps.who.int/gho/data/node.main.A887?lang=en; Overweight/Obesity: https://apps.who.int/gho/data/node.main.BMIOBESITYA?lang=en; (Accessed 15 January 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>World Health Organization data and statistics</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Non-communicable diseases: Prevalence of diabetes mellitus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0035" xlink:href="https://gateway.euro.who.int/en/indicators/hfa_379-2370-prevalence-of-diabetes-mellitus/" xlink:type="simple">https://gateway.euro.who.int/en/indicators/hfa_379-2370-prevalence-of-diabetes-mellitus/</ce:inter-ref>
                              <sb:date-accessed day="15" month="1" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">World Health Organization data and statistics. Non-communicable diseases: Prevalence of diabetes mellitus. https://gateway.euro.who.int/en/indicators/hfa_379-2370-prevalence-of-diabetes-mellitus/(Accessed 15 January 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.I.</ce:given-name>
                                 <ce:surname>Hay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Abajobir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Abate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Abbafati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Abbas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Abd-Allah</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>390</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1260</sb:first-page>
                              <sb:last-page>1344</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1260-1344.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>Global Burden of Disease Study</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>392</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1923</sb:first-page>
                              <sb:last-page>1994</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">Global Burden of Disease Study. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1923-1994.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Stanaway</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Afshin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gakidou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Abate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Abate</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>392</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1923</sb:first-page>
                              <sb:last-page>1994</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">Stanaway JD, Afshin A, Gakidou E, Lim SS, Abate D, Abate KH, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1923-1994.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:host>
                           <sb:book>
                              <sb:title>
                                 <sb:maintitle>WHO Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020</sb:maintitle>
                              </sb:title>
                              <sb:date>2013</sb:date>
                              <sb:publisher>
                                 <sb:name>World Health Organization</sb:name>
                                 <sb:location>Geneva</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0040" xlink:href="http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf" xlink:type="simple">http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf</ce:inter-ref>
                              <sb:date-accessed day="15" month="1" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">WHO Global Action Plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva: World Health Organization, 2013. http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf) (Accessed 15 January 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Khatib</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>McKee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shannon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rangarajan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Teo</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>387</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>61</sb:first-page>
                              <sb:last-page>69</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 2016;387:61-69.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Palafox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>O'Donnell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Stuckler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Perel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>AlHabib</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e292</sb:first-page>
                              <sb:last-page>e301</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">Murphy A, Palafox B, O'Donnell O, Stuckler D, Perel P, AlHabib KF, et al. Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. Lancet Glob Health 2018;6:e292-e301.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yusuf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Joseph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Teo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xavier</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Polypill with or without aspirin in persons without cardiovascular disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>384</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>216</sb:first-page>
                              <sb:last-page>228</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med 2021;384:216-228.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Roshandel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Khoshnia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Poustchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hemming</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Kamangar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gharavi</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>394</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>672</sb:first-page>
                              <sb:last-page>683</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019;394:672-683.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Muñoz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Uzoije</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Reynolds</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Walkley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pappalardo</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Polypill for cardiovascular disease prevention in an underserved population</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>381</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1114</sb:first-page>
                              <sb:last-page>1123</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">Munoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, et al. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med 2019;381:1114-1123.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yusuf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Joseph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Teo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xavier</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Polypill with or without aspirin in persons without cardiovascular disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>384</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>216</sb:first-page>
                              <sb:last-page>228</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med 2021;384:216-228</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Ference</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Bhatt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Catapano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Packard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kaptoge</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Med. Assoc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>322</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1381</sb:first-page>
                              <sb:last-page>1391</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA 2019;322:1381-1391.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Brandts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Low density lipoprotein cholesterol-lowering strategies and population health: time to move to a cumulative exposure model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Circulation</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>141</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>873</sb:first-page>
                              <sb:last-page>876</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">Brandts J, Ray KK. Low density lipoprotein cholesterol-lowering strategies and population health: time to move to a cumulative exposure model. Circulation 2020;141:873-876.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Stoekenbroek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kallend</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nishikido</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Leiter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Landmesser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.L.J.</ce:given-name>
                                 <ce:surname>Wijngaard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.P.</ce:given-name>
                                 <ce:surname>Kastelein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JAMA Cardiol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1067</sb:first-page>
                              <sb:last-page>1075</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, Wright RS, Wijngaard PLJ, Kastelein JJP. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol 2019;4:1067-1075.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Borén</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Chapman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Krauss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Packard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Bentzon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Binder</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. Heart J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2313</sb:first-page>
                              <sb:last-page>2330</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313-2330.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Wilemon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Aguilar-Salinas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Ahmed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Alkhnifsawi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Almahmeed</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JAMA Cardiol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>217</sb:first-page>
                              <sb:last-page>229</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, Almahmeed W, et al. Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol 2020;5:217-229.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>EAS Familial Hypercholesterolaemia Studies Collaboration</sb:collaboration>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Vallejo-Vaz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Akram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Kondapally Seshasai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cole</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.F.</ce:given-name>
                                 <ce:surname>Watts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.K.</ce:given-name>
                                 <ce:surname>Hovingh</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Atherosclerosis Suppl.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>32</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl 2016;22:1-32.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </simple-tail>
      </simple-article>
   </xocs:serial-item></xocs:doc></originalText></full-text-retrieval-response>